Clinical Trial Search

Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants

Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15

Primary: Progression-free Survival (PFS) > 6 Months — 4.3 percentage of participants

Primary: Progression-free Survival (PFS) > 6 Months — 0.0 percentage of participants

Primary: Objective Overall Response Rate — 2; 0 participants

Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…

Primary: Tumor Response — 0 percentage of participants

Primary: Objective Tumor Response (Complete or Partial) — 0 percentage of participants

Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients

Primary: Percentage of Patients With Objective Tumor Response Rate (Either Complete Response (CR) or Partial Response (PR) Using RECIST Version 1.0 — 8 Percentage of participants

Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months

Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…

Primary: Objective Tumor Response — 11.8 percentage

Primary: Cycles With Hematologic Toxicities — 11; 14; 6; 0 Cycles

Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants

Primary: Objective Response Rate (ORR) — 26 Percentage of participants

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Response Rate — 15.3 percentage of participants

Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…

Primary: Phase I: Maximum Tolerated Dose (MTD) of Trabectedin When Administered in Association With CP. — 0.50 mg/m^2

Primary: Tumor Response — 16.7 percentage of patients

Primary: Objective Response Rate — 6; 6; 16; 5 Participants

Primary: Participant Responses — 2; 8; 4; 6 participants

Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024

Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants

Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants

Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants